Gastrointestinal mesenchymal tumors, also known as gastrointestinal mesenchymal tumors, are a group of tumors that originate from the mesenchymal tissue of the gastrointestinal tract and account for most of the mesenchymal tumors of the GI tract. Gastrointestinal mesenchymal tumors (GISTs) account for 1 to 3% of malignant tumors of the gastrointestinal tract, with an estimated annual incidence of about 1 to 2/10,000, mostly in middle-aged and elderly patients, rare in patients under 40 years of age, and no significant difference in incidence between men and women. Most GISTs occur in the stomach (50-70%) and small intestine (20-30%), colorectum accounts for about 10-20%, esophagus accounts for 0-6%, mesenteric, omentum and retroperitoneum are rare. I. Clinical manifestations of gastrointestinal mesenchymal tumors 1. The symptoms of GISTs depend on the size and location of the tumor and are usually nonspecific. Gastrointestinal bleeding is the most common symptom. And in esophagus, dysphagia symptoms are often common as well. Some patients are seen for intestinal perforation, which can increase the risk of abdominal implantation and local recurrence. 2. Approximately 11-47% of patients with GISTs have metastases at the first visit. Metastases are mainly in the liver and abdominal cavity; lymph node and extra-abdominal metastases are relatively rare even in more advanced patients. Metastases can occur even 30 years after resection of the primary tumor. Small bowel GISTs have the highest rate of malignancy and lymph node metastasis, while esophageal GISTs are less malignant. Therefore, strictly speaking, GISTs are not benign, or at least a class of malignant tumors including potentially malignant. 3. CT, ultrasound endoscopy, and gastrointestinal imaging can assist in the determination of the size, local infiltration, metastasis, and location of GISTs. Treatment of gastrointestinal mesenchymal tumor The treatment of gastrointestinal mesenchymal tumor is a tricky thing, because it is difficult to detect in early stage, and the effect of conventional radiotherapy is poor. In recent years, with the development of molecular targeted therapeutic drugs, brand new targeted therapeutic drugs such as Gleevec (Imatinib) and Sotan (Sunitinib) have been developed and approved for the treatment of gastrointestinal mesenchymal tumors. In the field of gastrointestinal mesenchymal tumor treatment, Sotan (sunitinib), on the other hand, is the only drug approved by SFDA for GIST (gastrointestinal mesenchymal tumor) that has failed or is intolerant to imatinib treatment. In addition, the researchers found that 98% of patients who used once-daily 400 mg of the imatinib mesylate class of targeted drugs were recurrence-free within one year after surgery and were able to extend the average survival time of patients with advanced disease from 19 to 54 months, which tripled the survival time of patients. Meanwhile, if tumors are contained by targeted drugs before surgery, the success rate of surgery and the survival rate of patients after surgery can also be improved.